about
Ezetimibe for primary hypercholesterolemiaAlgorithms to Identify Statin Intolerance in Medicare Administrative Claim Data.Linkage of a Population-Based Cohort With Primary Data Collection to Medicare Claims: The Reasons for Geographic and Racial Differences in Stroke StudyEstimation of the burden of cardiovascular disease attributable to modifiable risk factors and cost-effectiveness analysis of preventative interventions to reduce this burden in Argentina.Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations.Global cardiovascular research output, citations, and collaborations: a time-trend, bibliometric analysis (1999-2008).Perfect storm: concurrent stress and depressive symptoms increase risk of myocardial infarction or deathCardiovascular research publications from Latin America between 1999 and 2008. A bibliometric study.Contrasting Cholesterol Management Guidelines for Adults with CKD.Development and Validation of the Framingham Steatosis Index to Identify Persons With Hepatic Steatosis.Disparities in cardiovascular research output and citations from 52 African countries: a time-trend, bibliometric analysis (1999-2008).The role of cystatin-C in the confirmation of reduced glomerular filtration rate among the oldest old.Zolpidem use and motor vehicle collisions in older drivers.Strategies for improving the quality of health care in maternal and child health in low- and middle-income countries: an overview of systematic reviews.A cost-effectiveness analysis of a 10-valent pneumococcal conjugate vaccine in children in six Latin American countries.Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality: A Cohort StudyAgreement between Medicare pharmacy claims, self-report, and medication inventory for assessing lipid-lowering medication use.Generalizability of SPRINT Results to the U.S. Adult PopulationCross-Cultural Adaptation of a Text Message-Based Program for Smoking Cessation in Buenos Aires, Argentina.Beat-to-beat heart rate and blood pressure variability and hypertensive disease in pregnancy.Managing residual risk after myocardial infarction among individuals with low cholesterol levels.Managing Residual Risk After Myocardial Infarction Among Individuals with Low Cholesterol Levels.Stroke symptoms and risk for incident coronary heart disease in the REasons for Geographic And Racial Differences in Stroke (REGARDS) study.Cost-effectiveness analysis of a cervical cancer vaccine in five Latin American countries.Healthy lifestyle factors and incident heart disease and mortality in candidates for primary prevention with statin therapy.Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction.Modifiable Risk Factors Versus Age on Developing High Predicted Cardiovascular Disease Risk in BlacksMetabolic syndrome and masked hypertension among African Americans: The Jackson Heart Study.Cardiovascular Health and Healthcare Utilization and Expenditures Among Medicare Beneficiaries: The REasons for Geographic And Racial Differences in Stroke (REGARDS) Study.Impact of metabolic syndrome on the hospitalization rate of Crohn's disease patients seen at a tertiary care center: a retrospective cohort study.Estimation and comparison of EQ-5D health states' utility weights for pneumococcal and human papillomavirus diseases in Argentina, Chile, and the United Kingdom.[Estimate of the cardiovascular disease burden attributable to modifiable risk factors in Argentina]Factors involved in the paradox of reverse epidemiologyDevelopment of algorithms for identifying fatal cardiovascular disease in Medicare claimsCosto-Efectividad de la Proteína C Reactiva, Procalcitonina y Escala de Rochester: Tres Estrategias Diagnosticas para la Identificación de Infección Bacteriana Severa en Lactantes Febriles sin FocoCharacteristics and Cardiovascular Disease Event Rates among African Americans and Whites Who Meet the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) Trial Inclusion CriteriaMedical Expenditures Among Medicare Beneficiaries with Statin-Associated Adverse Effects Following Myocardial Infarction
P50
Q24244704-203464B5-2685-4688-831E-24AC931B529BQ31113251-92B49E94-8144-4FDA-9592-F6210CB52F6DQ31132066-4C0B595B-08F7-4D46-8E59-19E812B20E16Q33723567-3476AF3F-D50A-40AC-91E3-5B9F62C92BD4Q34307407-70AB2AE6-2B74-4249-8994-3CFAC3B41A89Q35082477-339B5311-1AE2-41F8-9B8D-C3C2EFEF642DQ35196448-3F6B215C-0E9C-4A9C-866F-578F08ACE064Q35292422-5978C57E-5F86-40E9-B4E5-991CC88DE62DQ35550614-F886816C-4FE3-494E-92D5-BA1CD53A8010Q35980112-F1EA15C5-F7D5-47F4-A683-624F77ED3D12Q36085703-B021ED87-7F0A-4A6A-89E6-2D15CEDE44E4Q36582351-E029ED98-9776-4B74-9059-0D74275C994CQ37018749-8F8AEEBD-F639-46B8-826B-5153A0EFD23FQ37072930-8D6F2B69-0F69-4480-A902-A7B07A6CE552Q37153913-D261CEBC-71C4-4302-B027-12148C3998BCQ37253234-44327CE1-9E7F-41AF-89E6-C6AC1BD33BC5Q37291832-70EEC090-FAEC-4B17-BC41-180908C73FB1Q37586970-74828BAB-F860-4018-8198-A9C1CC00BFF1Q38386176-8B3B193C-9EA6-44D4-9D6A-A8AB5CFDDE10Q38413674-2D062C68-89E1-45E7-AB2D-0AA6A41B5568Q38457902-566A1337-25A2-47D3-BF2E-4CD2D5C6C8C8Q38740159-C8B39F41-FD5C-4683-8DFA-9EB8539A0AC9Q39633706-B848B4B4-F555-4506-B55B-8D762B3DF550Q39962064-33BB3DB3-A8C3-4AF7-AB93-433B04DEAB96Q40069426-1A1EE7F0-2A67-4021-9EDE-534310002C28Q40288806-D56643FC-6695-4FEC-8D29-B337FB576E5BQ40343861-C581C051-A0FD-45EC-98F9-A086CF0E5273Q40348365-4BB749D3-AE66-4632-8DD2-CF18EC35EFC8Q40354433-254239B6-CEB2-4B3C-AE62-7CF7F697738EQ41126415-A172D0FA-4A0E-4BC8-8736-180F1D680031Q47272113-732CC5E9-805B-4022-BB2C-7F22556497F6Q84329345-873783AA-3243-4B46-8C10-E3943ED39B0DQ87615946-F666B5AA-0B14-4FAD-AFF3-42484D989FF3Q88049647-717EFD4A-955D-45F2-A22F-7C9A202B46C6Q88495271-3A06E207-5A95-4563-B929-35FE25DFF83AQ91473028-CE9ADFB2-E374-4F26-936A-5DB198B9BF89Q93185326-E0B8D36D-E751-46B5-8106-7F9CF89CC184
P50
description
researcher ORCID ID = 0000-0001-8742-1788
@en
wetenschapper
@nl
name
Lisandro D Colantonio
@ast
Lisandro D Colantonio
@en
Lisandro D Colantonio
@es
Lisandro D Colantonio
@nl
type
label
Lisandro D Colantonio
@ast
Lisandro D Colantonio
@en
Lisandro D Colantonio
@es
Lisandro D Colantonio
@nl
prefLabel
Lisandro D Colantonio
@ast
Lisandro D Colantonio
@en
Lisandro D Colantonio
@es
Lisandro D Colantonio
@nl
P106
P1153
23481285400
P21
P31
P496
0000-0001-8742-1788